Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 892182, 8 pages
http://dx.doi.org/10.1155/2012/892182
Research Article

Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial

1Departamento de Química, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
2Hospital Universitário de Santa Maria, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
3Departamento de Biologia, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
4Departamento de Farmácia Industrial, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
5Departamento de Morfologia, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil

Received 26 March 2011; Revised 18 June 2011; Accepted 23 June 2011

Academic Editor: Angelo Antonio Izzo

Copyright © 2012 I. L. G. Farias et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

To evaluate the effectiveness of Uncaria tomentosa in minimizing the side effects of chemotherapy and improving the antioxidant status of colorectal cancer (CRC) patients, a randomized clinical trial was conducted. Patients (43) undergoing adjuvant/palliative chemotherapy with 5-Fluorouracil/leucovorin + oxaliplatin (FOLFOX4) were split into two groups: the UT group received chemotherapy plus 300 mg of Uncaria tomentosa daily and the C group received only FOLFOX4 and served as a control. Blood samples were collected before each of the 6 cycles of chemotherapy, and hemograms, oxidative stress, enzymes antioxidants, immunologic parameters, and adverse events were analyzed. The use of 300 mg of Uncaria tomentosa daily during 6 cycles of FOLFOX4 did not change the analyzed parameters, and no toxic effects were observed.